

FORM PTO-1390  
(REV. 12-2001)

DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

700.001

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/089742

INTERNATIONAL APPLICATION NO.  
PCT/GB00/03806INTERNATIONAL FILING DATE  
October 4, 2000PRIORITY DATE CLAIMED  
October 4, 1999

TITLE OF INVENTION

Targeted Gene Therapy

APPLICANT(S) FOR DO/EO/US


JAN BROSENS

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information:

U.S. APPLICATION NO. 10/089742 INTERNATIONAL APPLICATION NO. PCT/GB00/03806		ATTORNEY'S DOCKET NUMBER 700.001	
21. <input checked="" type="checkbox"/> The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. .... <b>\$1040.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... <b>\$890.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... <b>\$740.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... <b>\$710.00</b>  International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... <b>\$100.00</b>  <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>		<b>CALCULATIONS PTO USE ONLY</b>	
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$ 890.00  \$ 130.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	23 - 20 =	3	x <b>\$18.00</b>
Independent claims	3 - 3 =	0	x <b>\$84.00</b>
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ <b>\$280.00</b>
<b>TOTAL OF ABOVE CALCULATIONS</b>		= \$ 1354.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		+ \$ - 677.00	
<b>SUBTOTAL</b>		= \$ 677.00	
Processing fee of <b>\$130.00</b> for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$	
<b>TOTAL NATIONAL FEE</b>		= \$ 677.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +		\$	
<b>TOTAL FEES ENCLOSED</b>		= \$ 677.00	
		Amount to be refunded:	\$
		charged:	\$ 677.00
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed.  b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.  c. <input type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. _____. A duplicate copy of this sheet is enclosed.  d. <input checked="" type="checkbox"/> Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card          information should not be included on this form.</b> Provide credit card information and authorization on PTO-2038.  <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to the credit card listed on PTO-2038.			
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.</b>			
SEND ALL CORRESPONDENCE TO: GEHRKE & ASSOCIATES, S.C. 610 North 77th Street Wauwatosa, WI 53213 USA Tel. 414.774.0874 Fax 414.774.4837 email: lgehrke@gehrke-law.com		 SIGNATURE LISA M. GEHRKE NAME 38,888 REGISTRATION NUMBER	

GEHRKE & ASSOCIATES  
INTELLECTUAL PROPERTY LAW

10/089742

IC10 Rec'd PCT/PTO 02 APR 2002

Lisa M. Gehrke  
lgehrke@gehrke-law.com

Lisa A. Brzycki, Patent Agent  
lbrzycki@gehrke-law.com

April 2, 2002

Commissioner of Patents and Trademarks  
Box PCT  
Washington, DC 20231


Re: New U.S. Patent Application (*National Stage*)  
TARGETED GENE THERAPY  
Applicant: JAN BROSENS  
Based on: PCT/GB00/03806  
Int'l Filing Date: October 4, 2000  
Priority Appl.: GB 9923381.9  
Priority Filing Date: October 4, 1999  
Atty Docket No.: 700.001  
Customer. No.: 32,123

Dear Sir:

Enclosed is a Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. 371 (PTO-1390) enclosing 35 pages of as-filed specification, 23 claims, and 5 sheets of drawings. The executed Oath/Declaration and an Assignment will be filed at a later date.

This National Stage U.S. filing is based on PCT/GB00/03806 with an International Filing Date of October 4, 2000.

Respectfully submitted,


  
Lisa M. Gehrke  
Reg. No. 38,888

Certification Under 37 CFR 1.10

Express Mail Label No: EU336712920US

Date of Deposit: April 2, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service in "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Box PCT, Washington, D.C. 20231.

  
Lisa A. Brzycki

Z:\CLIENTS\700 - DEHN\001\TRANSMITTAL LETTER.DOC

123 North 86<sup>th</sup> Street, Wauwatosa, Wisconsin, 53226, USA

Mailing Address:  
610 North 77<sup>th</sup> Street  
Wauwatosa, WI 53213-3512  
USA

Voice (414) 774-0874  
Fax (414) 774-4837  
www.gehrke-law.com